Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …

Background and aims Molnupiravir is a newer oral antiviral drug that has recently received
emergency use authorization (EUA) in USA, UK and India. We aim to conduct an update on …

Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Introduction At present, there are some differences in the research results of molnupiravir.
The purpose of this study was to evaluate the efficacy and safety of molnupiravir in the …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …

The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …